Lung Cancer | Specialty

Dr. Aggarwal on Investigational Biomarkers in Lung Cancer

October 16th 2020

Charu Aggarwal, MD, MPH, discusses investigational biomarkers in lung cancer.

Navigating Newfound Options in SCLC With Immunotherapy and Lurbinectedin

October 16th 2020

Rafael Santana-Davila, MD, discusses the introduction of immunotherapy and lurbinectedin to the SCLC armamentarium, as well as areas in need of additional research.

RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

October 14th 2020

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

PD-1/CTLA-4 Combos, Broader Patient Population Are Next Steps With Immunotherapy in Locally Advanced NSCLC

October 12th 2020

David Gerber, MD, highlights the impact of the PACIFIC trial and other next steps with immunotherapy in patients with stage III NSCLC.

Next Steps in Small Cell Lung Cancer Feature Closer Eye on Immunotherapy, Lurbinectedin

October 8th 2020

Benjamin Drapkin, MD, PhD, discusses the road ahead in small cell lung cancer research, and the challenges that still need to be solved in the first- and second-line settings.

PD-1 Inhibition Reigns Supreme in Advanced Squamous NSCLC

October 7th 2020

Ronan J. Kelly, MD, MBA, explains how the results of the KEYNOTE-407 trial have positioned pembrolizumab plus chemotherapy as the frontline standard of care in this setting.

Neoadjuvant Nivolumab/Chemo Combo Significantly Improves pCR in Resectable NSCLC

October 7th 2020

The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.

Sotorasib Shows Durable Antitumor Activity in KRAS G12C–Mutant Advanced NSCLC

October 6th 2020

Sotorasib demonstrated durable responses in patients with KRAS G12C–mutated advanced non–small cell lung cancer who had progressed on a median of 2 previous lines of treatment.

Mobocertinib Continues to Show Clinical Activity in EGFR Exon 20–Mutant NSCLC

October 5th 2020

Mobocertinib elicited a 43% objective response rate and an 86% disease control rate in select patients with non–small cell lung cancer who have EGFR exon 20 insertion mutations.

Dr. Gainor on the Evolving Lung Cancer Armamentarium

October 5th 2020

Justin F. Gainor, MD, discusses the evolving lung cancer armamentarium.

Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

October 2nd 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

Dr. Giaccone on Treatment Options in NSCLC

October 1st 2020

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC

October 1st 2020

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

NSCLC Treatment Portfolio Gains RET-Targeted Therapy

October 1st 2020

In an interview with OncologyLive®, Justin F. Gainor, MD, discusses the impact pralsetinib may have on the RET-altered NSCLC paradigm.

Dr. Reck on the Safety of Pembrolizumab in KEYNOTE-024 in Metastatic NSCLC

September 30th 2020

Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.

EGFR-Mutated NSCLC: Looking Ahead

September 29th 2020

RELAY Trial Regimen Adverse-Event Overview

September 29th 2020

TKI Plus Antiangiogenic Combination Therapy

September 29th 2020

TKI Combination Clinical Trials: Practical Implications in US and UK

September 29th 2020

EGFR TKI Plus Chemotherapy Combination Strategy

September 29th 2020